so they say in the announcement they are now looking forward to the FDA decision on Bronchitol and the focus now is on the anti cancer lox inhibitor program.
So I guess a potential LOXL2 sale is dead and buried as well, no mention of the usual blurb about "progressing potential partners for LOXL2..... another fail I guess that no one wants it after nearly 2 years on the market.
Ann: Boehringer Ingelheim discontinues development of BI 1467335, page-5
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $33.43M | |||
| Open | High | Low | Value | Volume |
| 2.8¢ | 2.9¢ | 2.8¢ | $5.694K | 203.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 311572 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 257306 | 2 |
View Market Depth
| Last trade - 10.29am 18/06/2024 (20 minute delay) ? |
|
|||||
|
Last
2.8¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 2.8¢ | 2.8¢ | 2.8¢ | 90040 | ||
| Last updated 10.42am 18/06/2024 ? | |||||
| SNT (ASX) Chart |
